Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 69,832 Shares

by · The Cerbat Gem

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) CEO Vishwas Seshadri sold 69,832 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total transaction of $372,204.56. Following the transaction, the chief executive officer owned 1,460,408 shares of the company’s stock, valued at $7,783,974.64. This trade represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vishwas Seshadri also recently made the following trade(s):

  • On Monday, December 29th, Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock. The shares were sold at an average price of $5.31, for a total transaction of $132,750.00.

Abeona Therapeutics Price Performance

Shares of ABEO stock traded up $0.05 during trading hours on Thursday, hitting $5.36. The company’s stock had a trading volume of 1,363,791 shares, compared to its average volume of 982,818. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $5.07 and a 200-day moving average of $5.64. Abeona Therapeutics Inc. has a twelve month low of $3.93 and a twelve month high of $7.54. The stock has a market cap of $290.46 million, a price-to-earnings ratio of 4.36 and a beta of 1.12.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. As a group, equities research analysts anticipate that Abeona Therapeutics Inc. will post -1.16 EPS for the current year.

Hedge Funds Weigh In On Abeona Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Boone Capital Management LLC purchased a new position in Abeona Therapeutics during the second quarter worth about $7,126,000. AWM Investment Company Inc. purchased a new stake in Abeona Therapeutics in the 2nd quarter valued at about $2,670,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $581,000. Simplify Asset Management Inc. lifted its holdings in shares of Abeona Therapeutics by 36.7% during the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock worth $3,173,000 after acquiring an additional 150,000 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Abeona Therapeutics in the second quarter worth approximately $1,523,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research note on Monday, October 13th. Finally, Weiss Ratings downgraded shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Abeona Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Check Out Our Latest Stock Report on Abeona Therapeutics

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

Recommended Stories